A Phase I Dose Escalation Study of MK0457 Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer
- Patients who are at least 18 years of age with recurrent or non-responsive solid
tumors, or cancers for which standard therapy does not exist.
- Patients who have had treatment with any investigational therapy within the past 30
- Patients who have certain types of blood cancers such as leukemia or lymphoma.
- Patients who have uncontrolled congestive heart failure (CHF), chest pains, or had a
heart attack within the past 3 months, or have undergone bone marrow or stem cell
- Patient is pregnant or nursing.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety and tolerability of a 24 hour CIV infusion every 21 days
Outcome Time Frame:
United States: Food and Drug Administration